Jump to content

2-Imidazoline

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 13:02, 13 April 2011 (Updating {{chembox}} (changes to watched fields - updated 'UNII_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation (report errors or [[user talk:). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

2-Imidazoline
Names
IUPAC name
4,5-Dihydro-1H-imidazole
Identifiers
3D model (JSmol)
ChemSpider
ECHA InfoCard 100.007.273 Edit this at Wikidata
  • InChI=1S/C3H6N2/c1-2-5-3-4-1/h3H,1-2H2,(H,4,5) checkY
    Key: MTNDZQHUAFNZQY-UHFFFAOYSA-N checkY
  • InChI=1/C3H6N2/c1-2-5-3-4-1/h3H,1-2H2,(H,4,5)
    Key: MTNDZQHUAFNZQY-UHFFFAOYAB
  • N\1=C\NCC/1
Properties
C3H6N2
Molar mass 70.095 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
checkY verify (what is checkY☒N ?)

Imidazoline is a nitrogen-containing heterocycle with formula C3H6N2, derived from imidazole. The ring contains an imine bond, and the carbons at the 4 and 5 positions are singly bonded, rather than doubly bonded for the case of imidazole. Imidazolines are structurally related to guanidines and amidines.

Chemical relationship of imidazole to its reduced derivatives.


Second generation Grubbs' catalyst

Like imidazole, imidazoline-based compounds have been used as N-heterocyclic carbene ligands on various transition metals. It is found in the commercially available second generation Grubbs' catalyst.

Biological role

Many imidazolines are biologically active.[1] Most bio-active derivatives bear a substituent (aryl or alkyl group) on the carbon between the nitrogen centers. Some generic names include oxymetazoline, xylometazoline, tetrahydrozoline, and naphazoline.

See also

References

  1. ^ N. MacInnes and S. Duty (2004). "Locomotor effects of imidazoline I2-site-specific ligands and monoamine oxidase inhibitors in rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathway". Br J Pharmacol. 143 (8): 952–959. doi:10.1038/sj.bjp.0706019. PMC 1575965. PMID 15545290.